应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06887 东阳光药
未开盘 06-12 16:08:21
34.640
+0.640
+1.88%
最高
35.000
最低
33.920
成交量
18.60万
今开
34.320
昨收
34.000
日振幅
3.18%
总市值
199.53亿
流通市值
110.85亿
总股本
5.76亿
成交额
642.27万
换手率
0.06%
流通股本
3.20亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
东阳光药更新5月股份变动月报表,H股增至321,103,140股
公告速递 · 06-03
东阳光药更新5月股份变动月报表,H股增至321,103,140股
东阳光药(06887)委任郑程杰为授权代表
智通财经 · 05-29
东阳光药(06887)委任郑程杰为授权代表
东阳光药拟回购最多10%股份
公告速递 · 05-28
东阳光药拟回购最多10%股份
东阳光药(06887)建议委任蒋均才为执行董事
智通财经 · 05-28
东阳光药(06887)建议委任蒋均才为执行董事
东阳光药(06887):2.08亿股内股资转换为H股
智通财经 · 05-22
东阳光药(06887):2.08亿股内股资转换为H股
东阳光药(06887):完成H股全流通
智通财经 · 05-21
东阳光药(06887):完成H股全流通
东阳光药(06887):联交所就H股全流通授予上市批准
智通财经 · 05-06
东阳光药(06887):联交所就H股全流通授予上市批准
东阳光药公布4月股份变动月报 股本维持稳定
公告速递 · 05-06
东阳光药公布4月股份变动月报 股本维持稳定
东阳光药(06887):甘精胰岛素注射液获得美国食品药品监督管理局的上市批准
智通财经 · 05-04
东阳光药(06887):甘精胰岛素注射液获得美国食品药品监督管理局的上市批准
东阳光药2025年营收48.15亿元 扭亏为盈实现归母净利2.72亿元
公告速递 · 04-30
东阳光药2025年营收48.15亿元 扭亏为盈实现归母净利2.72亿元
东阳光药(06887):中国证监会就公司H股全流通申请出具备案通知书
智通财经 · 04-29
东阳光药(06887):中国证监会就公司H股全流通申请出具备案通知书
东阳光药4月28日回购700股股份,总额约2.89万港元
公告速递 · 04-28
东阳光药4月28日回购700股股份,总额约2.89万港元
东阳光药(06887)4月28日斥资2.89万港元回购700股
智通财经 · 04-28
东阳光药(06887)4月28日斥资2.89万港元回购700股
东阳光药4月23日回购1300股股份,总额约5.43万港元
公告速递 · 04-23
东阳光药4月23日回购1300股股份,总额约5.43万港元
东阳光药(06887)4月23日斥资5.43万港元回购1300股
智通财经 · 04-23
东阳光药(06887)4月23日斥资5.43万港元回购1300股
东阳光药(06887):三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局
智通财经 · 04-23
东阳光药(06887):三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局
东阳光药4月21日回购6000股股份,总额约26.35万港元
公告速递 · 04-21
东阳光药4月21日回购6000股股份,总额约26.35万港元
东阳光药回购2,000股股份,总额约8.86万港元
公告速递 · 04-20
东阳光药回购2,000股股份,总额约8.86万港元
东阳光药(06887)4月20日斥资8.86万港元回购2000股
智通财经 · 04-20
东阳光药(06887)4月20日斥资8.86万港元回购2000股
东阳光药:4月17日回购2,500股,耗资约11.13万港元
公告速递 · 04-17
东阳光药:4月17日回购2,500股,耗资约11.13万港元
公司概况
公司名称:
东阳光药
所属市场:
SEHK
上市日期:
--
主营业务:
广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药,亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威(磷酸奥司他韦),用于治疗流行性感冒(特别是甲型及乙型流行性感冒病毒),东卫恩(磷酸依米他韦),用于治疗丙型肝炎,及主要用于治疗敏感细菌引起的感染的仿制药,即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病,包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。
发行价格:
--
{"stockData":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"东阳光药","latestPrice":34.64,"timestamp":1781251701009,"preClose":34,"halted":0,"volume":185964,"delay":0,"changeRate":0.01882352941176472,"floatShares":320000000,"shares":576000000,"eps":0.6373413307841787,"marketStatus":"未开盘","change":0.64,"latestTime":"06-12 16:08:21","open":34.32,"high":35,"low":33.92,"amount":6422662,"amplitude":0.031765,"askPrice":34.64,"askSize":7000,"bidPrice":34.56,"bidSize":700,"shortable":3,"etf":0,"ttmEps":0.6072124678743811,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":0,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":34,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":0.31155624996755577,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06887/wiki","defaultTab":"wiki","newsList":[{"id":"1164094154","title":"东阳光药更新5月股份变动月报表,H股增至321,103,140股","url":"https://stock-news.laohu8.com/highlight/detail?id=1164094154","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164094154?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:06","pubTimestamp":1780484774,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年6月3日公布2026年5月股份变动月报表。根据公告,截至2026年5月31日,公司法定注册股本总额为人民币576,656,047元,其中H股由上月底的112,712,832股增加208,390,308股至321,103,140股,内资股则由463,943,215股减少至255,552,907股。公司当月没有披露任何新增发行、回购、注销或库藏股变动,也无股份期权、可转债或其他股权激励计划的变动信息。公司同时确认其公众持股比例符合相关上市规则要求。本次月报由公司董事张英俊签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639754776","title":"东阳光药(06887)委任郑程杰为授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2639754776","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639754776?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:57","pubTimestamp":1780066670,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)公布,公司的执行董事兼总经理李文佳博士将不再担任香港联合交易所有限公司证券上市规则第3.05条项下公司的其中一位授权代表,公司秘书郑程杰先生已获委任为授权代表,自2026年5月29日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115021686","title":"东阳光药拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1115021686","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115021686?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:11","pubTimestamp":1779977514,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司宣布,拟向董事会授予一项股份购回授权,回购数量将不超过已发行股份总数的10%,该授权需于2026年6月18日召开的股东周年大会审议通过。董事会重申,此次回购授权计划需经股东正式批准方可生效,并将严格遵守相关法律法规及上市规则。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638691898","title":"东阳光药(06887)建议委任蒋均才为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2638691898","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638691898?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:05","pubTimestamp":1779977135,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药 发布公告,公司第一届董事会的任期即将届满。根据相关法律法规及公司章程的要求,上述第二届董事会董事的建议委任,须经股东于股东大会上批准后方可作实。上述各董事候选人的任期均为3年,自公司股东大会审议通过之日起计算。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637312573","title":"东阳光药(06887):2.08亿股内股资转换为H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637312573","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637312573?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:10","pubTimestamp":1779455411,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,于2026年5月21日,2.08亿股内资股转换为H股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637732385","title":"东阳光药(06887):完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2637732385","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637732385?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:47","pubTimestamp":1779353249,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,2.08亿股内资股转换为H股已于2026年5月21日完成,而该等已转换H股将于2026年5月22日上午九时正开始于联交所上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633850421","title":"东阳光药(06887):联交所就H股全流通授予上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2633850421","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633850421?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:02","pubTimestamp":1778061771,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,联交所已于2026年5月5日授予上市批准及准许买卖根据H股全流通及转换及上市由内资股转换而来的2.08亿股H股。转换及上市将涉及本公司合共29名参与股东,合计2.08亿股内资股,占本公司于本公告日期已发行股本(计及库存股份)总额约36.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IPOS","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181862677","title":"东阳光药公布4月股份变动月报 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1181862677","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181862677?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:12","pubTimestamp":1778058743,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年5月6日发布截至2026年4月30日的证券变动月报表。报告期内,公司注册股本总额保持为人民币576,656,047元,其中H股112,712,832股,内资股463,943,215股,面值均为每股人民币1元。内资股于本月无增减,保持已发行及库存股份数量各463,943,215股和0股不变。公司未披露任何当月新增股份发行、可换股票据、期权授予及股权激励计划的变动。公司总股本于报告期末保持稳定。该公告由董事张英俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632813969","title":"东阳光药(06887):甘精胰岛素注射液获得美国食品药品监督管理局的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2632813969","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632813969?lang=zh_cn&edition=full","pubTime":"2026-05-04 08:27","pubTimestamp":1777854421,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药 发布公告,本集团自主研发的甘精胰岛素注射液获得美国食品药品监督管理局签发的批准信。美国市场及订单情况:本集团甘精胰岛素注射液已成功获得FDA批准上市,正推进门冬胰岛素在美国的开发。本次甘精胰岛素注射液获得FDA批准,为其加速拓展全球市场奠定了至关重要的准入基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IPOS","06887","159151"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123300059","title":"东阳光药2025年营收48.15亿元 扭亏为盈实现归母净利2.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123300059","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123300059?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:39","pubTimestamp":1777538398,"startTime":"0","endTime":"0","summary":"东阳光药在2025年度实现收入人民币48.15亿元,较2024年的40.19亿元增长19.81%。公司毛利为36.85亿元,毛利率由上年的76.11%提升至76.54%。归属于公司权益股东的净利润录得2.72亿元,相比2024年亏损2.07亿元,出现大幅扭亏为盈;净利润率由0.62%升至5.61%。经营溢利达6.69亿元,除税前溢利为4.40亿元,各项盈利指标均显著增长。每股基本收益为人民币0.56元,上年同期为每股基本亏损0.47元。公司年内经营活动所得现金净额达11.55亿元,较上年增长130.54%,显示经营现金流量明显改善。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药2025年营收48.15亿元 扭亏为盈实现归母净利2.72亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631597371","title":"东阳光药(06887):中国证监会就公司H股全流通申请出具备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2631597371","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631597371?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:46","pubTimestamp":1777459565,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,于2026年4月29日,本公司收到中国证监会就本次H股全流通申请出具日期为2026年4月27日《关于广东东阳光药业股份有限公司境内未上市股份“全流通”备案通知书》(备案通知书)。据此,本公司已就本次H股全流通向中国证监会完成备案。根据备案通知书,若本公司自备案通知书出具之日起12个月内未完成本次H股全流通转换及上市,如拟继续推进,应当更新备案材料。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药(06887):中国证监会就公司H股全流通申请出具备案通知书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153379507","title":"东阳光药4月28日回购700股股份,总额约2.89万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153379507","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153379507?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:47","pubTimestamp":1777369667,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年4月28日公告回购700股H股,占当日公司已发行股本约0.0006%。本次回购价格介乎每股41.08港元至41.44港元,总金额28,870港元,约合2.89万港元。回购完成后,公司已发行股份总数仍为112,712,832股,其中112,035,232股为流通股,库藏股增至677,600股。公司确认已遵守香港联合交易所有限公司的相关上市规则及有关法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药4月28日回购700股股份,总额约2.89万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630374149","title":"东阳光药(06887)4月28日斥资2.89万港元回购700股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630374149","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630374149?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:44","pubTimestamp":1777369441,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,于2026年4月28日,该公司斥资2.89万港元回购700股股份,每股回购价41.08-41.44港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115717996","title":"东阳光药4月23日回购1300股股份,总额约5.43万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115717996","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115717996?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:34","pubTimestamp":1776940496,"startTime":"0","endTime":"0","summary":"东阳光药于2026年4月23日在香港联交所场内回购1300股股份,占公司现有已发行股本约0.0012%。本次回购每股价格介乎港币41.52港元至41.90港元,合计耗资约54,256港元。回购完成后,公司已发行股本变动为112,035,932股,库藏股数为676,900股,已发行股本总数保持112,712,832股。公司购回授权于2025年12月16日获股东大会通过,最多可回购57,665,604股。公司确认,本次回购遵守香港联交所上市规则及相关法例。公告由董事张英俊签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药4月23日回购1300股股份,总额约5.43万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629880347","title":"东阳光药(06887)4月23日斥资5.43万港元回购1300股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629880347","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629880347?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:27","pubTimestamp":1776940059,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,于2026年4月23日该公司斥资5.43万港元回购1300股,回购价格为每股41.52-41.90港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629880358","title":"东阳光药(06887):三款创新药亮相2026年AACR年会展示肿瘤免疫与精准靶向治疗领域多元化管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2629880358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629880358?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:25","pubTimestamp":1776939928,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药 发布公告,于2026年4月17日至22日在美国加利福尼亚州圣地亚哥举行的 2026年美国癌症研究协会年会上,本集团以三份壁报形式集中展示了肿瘤治疗领域三款在研管线的最新临床前研究成果。上述三款创新药物在AACR年会上的集中亮相,不仅丰富了本集团的差异化产品管线,更展现了本集团在攻克不可成药靶点及开发下一代免疫疗法方面的技术积累与战略决心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1191","159992","BK1574","06978","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118184902","title":"东阳光药4月21日回购6000股股份,总额约26.35万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118184902","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118184902?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:10","pubTimestamp":1776766259,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年4月21日公告回购6000股H股普通股份,占当日已发行股本约0.0054%。本次回购价格区间介乎每股43.58港元至44.12港元,涉及总金额约263,504港元。完成回购后,公司已发行股本由原先的112,043,232股降至112,037,232股,库藏股数量由669,600股增至675,600股。截至公告日,公司已累计回购675,600股,剩余额度为56,990,004股。公司同时确认,此次回购事务已遵守香港联交所上市规则及相关法例规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药4月21日回购6000股股份,总额约26.35万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168981507","title":"东阳光药回购2,000股股份,总额约8.86万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168981507","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168981507?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:12","pubTimestamp":1776683527,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司(下称“东阳光药”,股票代码:06887)2026年4月20日发布公告,披露最新股份回购进展。\n公告显示,公司于当日通过香港联交所场内回购2,000股H股,占公司已发行股本约0.0018%。回购价格介乎每股44.18港元至44.46港元,涉资总额约8.86万港元。\n回购完成后,公司已发行股本变动至112,043,232股,库藏股数量增至669,600股。根据公告,公司于2025年12月16日获股东大会批准购回授权,可回购股份总数为57,665,604股。\n公司同时确认,相关回购程序已遵守香港联交所上市规则及相关法律规定。本次公告由董事张英俊签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628900742","title":"东阳光药(06887)4月20日斥资8.86万港元回购2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628900742","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628900742?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:07","pubTimestamp":1776683246,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东阳光药(06887)发布公告,于2026年4月20日斥资8.86万港元回购2000股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153727934","title":"东阳光药:4月17日回购2,500股,耗资约11.13万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153727934","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153727934?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:22","pubTimestamp":1776424959,"startTime":"0","endTime":"0","summary":"广东东阳光药业股份有限公司于2026年4月17日公告回购股份。公司当日于香港联交所场内回购2,500股,约占已发行股本的0.0022%。每股回购价介乎港币44.18元至44.66元,总金额为港币111,250元。回购完成后,公司已发行股本总数维持在112,712,832股,其中112,045,232股为公众持股,库藏股为667,600股。公司此前于2025年12月16日获得回购授权,可回购最多57,665,604股。公司确认本次股份回购严格遵守上市规则和相关法规。公告由公司董事张英俊签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0142},{"period":"1month","weight":-0.1476},{"period":"3month","weight":-0.1721},{"period":"6month","weight":-0.1819},{"period":"1year","weight":-0.425},{"period":"ytd","weight":-0.2404}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广东东阳光药业股份有限公司是一家主要从事药物的研发、生产和商业化的中国公司。该公司专注于创新药,亦涉及改良型新药、仿制药和生物类似药。该公司的抗感染产品包括可威(磷酸奥司他韦),用于治疗流行性感冒(特别是甲型及乙型流行性感冒病毒),东卫恩(磷酸依米他韦),用于治疗丙型肝炎,及主要用于治疗敏感细菌引起的感染的仿制药,即克拉霉素、左氧氟沙星及盐酸莫西沙星。该公司的慢病治疗药物主要专注于治疗糖尿病、高尿酸血症、高血压及胃酸相关疾病,包括胰岛素产品及仿制药。该公司还关注肿瘤治疗领域。","exchange":"SEHK","name":"东阳光药","nameEN":"SUNSHINE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光药,06887,东阳光药股票,东阳光药股票老虎,东阳光药股票老虎国际,东阳光药行情,东阳光药股票行情,东阳光药股价,东阳光药股市,东阳光药股票价格,东阳光药股票交易,东阳光药股票购买,东阳光药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光药(06887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光药(06887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}